Literature DB >> 32062286

Candida auris candidaemia in an intensive care unit - Prospective observational study to evaluate epidemiology, risk factors, and outcome.

Prakash S Shastri1, Shamanth A Shankarnarayan2, Jaswinder Oberoi3, Shivaprakash M Rudramurthy4, Chand Wattal3, Arunaloke Chakrabarti5.   

Abstract

PURPOSE: To determine the prevalence of Candida auris candidaemia in our ICU patients and its molecular epidemiology.
METHODS: A prospective observational study was conducted on candidaemia in our ICU patients over 18 months during 2016-2017. Demographics, underlying disease, risk factors, antifungal therapy and outcome were studied. Risk factors of C. auris and non-auris candidaemia were compared.
RESULTS: During the study period, among 108 candidaemia cases recorded, the incidence was 6.75/1000 ICU bed days. C. auris topped the list (n = 42, 39.9%), followed by C. tropicalis (34.3%), and C. parapsilosis (15.7%). On bivariate analysis prior antibiotic therapy, long central line days, mechanical ventilation and length of ICU stay were significant risk factors for C. auris candidaemia compared to non-auris candidaemia. Multivariate analysis showed underlying respiratory and neurological diseases as significantly associated with risk of C. auris candidaemia. Fluconazole, amphotericin B, and caspofungin resistance were noted in 97.0%, 93.7% and 3% of C. auris isolates respectively.
CONCLUSION: Longer duration of central line days, prior antibiotic use, mechanical ventilation and prolonged ICU stay were important risk factors associated with C. auris candidaemia along with underlying respiratory or neurological disease. The isolates are non-clonal in origin, but they belong to a single clade.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Candia auris; Candidaemia; ICU; Mortality; Risk factors

Mesh:

Substances:

Year:  2020        PMID: 32062286     DOI: 10.1016/j.jcrc.2020.01.004

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  15 in total

Review 1.  Candida auris, a singular emergent pathogenic yeast: its resistance and new therapeutic alternatives.

Authors:  Liliana Fernandes; Rita Ribeiro; Mariana Henriques; Maria Elisa Rodrigues
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-10-06       Impact factor: 5.103

2.  Transcriptional Response of Candida auris to the Mrr1 Inducers Methylglyoxal and Benomyl.

Authors:  Amy R Biermann; Deborah A Hogan
Journal:  mSphere       Date:  2022-04-27       Impact factor: 5.029

3.  In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in Candida auris.

Authors:  Jeffrey M Rybak; Katherine S Barker; José F Muñoz; Josie E Parker; Suhail Ahmad; Eiman Mokaddas; Aneesa Abdullah; Rehab S Elhagracy; Steve L Kelly; Christina A Cuomo; P David Rogers
Journal:  Clin Microbiol Infect       Date:  2021-12-13       Impact factor: 13.310

Review 4.  Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections.

Authors:  Mahmoud Ghannoum; Maiken Cavling Arendrup; Vishnu P Chaturvedi; Shawn R Lockhart; Thomas S McCormick; Sudha Chaturvedi; Elizabeth L Berkow; Deven Juneja; Bansidhar Tarai; Nkechi Azie; David Angulo; Thomas J Walsh
Journal:  Antibiotics (Basel)       Date:  2020-08-25

Review 5.  Candida auris: Epidemiology, Diagnosis, Pathogenesis, Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of Infections in Healthcare Facilities.

Authors:  Suhail Ahmad; Wadha Alfouzan
Journal:  Microorganisms       Date:  2021-04-11

6.  Axillary Digital Thermometers uplifted a multidrug-susceptible Candida auris outbreak among COVID-19 patients in Brazil.

Authors:  João Nobrega de Almeida; Igor B Brandão; Elaine C Francisco; Silvio Luis R de Almeida; Patrícia de Oliveira Dias; Felicidade M Pereira; Fábio Santos Ferreira; Thaisse Souza de Andrade; Magda M de Miranda Costa; Regiane T de Souza Jordão; Jacques F Meis; Arnaldo L Colombo
Journal:  Mycoses       Date:  2021-06-07       Impact factor: 4.931

7.  Photodynamic Therapy Is Effective Against Candida auris Biofilms.

Authors:  Priyanka S Bapat; Clarissa J Nobile
Journal:  Front Cell Infect Microbiol       Date:  2021-09-03       Impact factor: 5.293

8.  Evaluation of Candida auris acquisition in US international travellers using a culture-based screening protocol1.

Authors:  Instructor Sarah E Turbett; Doctoral Student Margaret Becker; Medical Technologist Barbara Belford; Research Technologist Meagan Kelly; Medical Technologist Lisa Desrosiers; Research Nurse Elizabeth Oliver; Associate Professor John A Branda; Epidemiologist Maroya Walters; Epidemiologist Allison Taylor Walker; Associate Professor Regina LaRocque; Professor Edward T Ryan
Journal:  J Travel Med       Date:  2022-01-17       Impact factor: 8.490

Review 9.  On the emergence, spread and resistance of Candida auris: host, pathogen and environmental tipping points.

Authors:  Arunaloke Chakrabarti; Prashant Sood
Journal:  J Med Microbiol       Date:  2021-02-18       Impact factor: 2.472

10.  Candida auris infection and biofilm formation: going beyond the surface.

Authors:  Mark V Horton; Jeniel E Nett
Journal:  Curr Clin Microbiol Rep       Date:  2020-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.